Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 12 result(s)
Content type(s)
CTD is a robust, publicly available database that aims to advance understanding about how environmental exposures affect human health. It provides manually curated information about chemical–gene/protein interactions, chemical–disease and gene–disease relationships. These data are integrated with functional and pathway data to aid in development of hypotheses about the mechanisms underlying environmentally influenced diseases. We also have additional ongoing projects involving manual curation of exposome data and chemical–phenotype relationships to help identify pre–disease biomarkers resulting from environmental exposures. The initial release of CTD was on November 12, 2004. We’re grateful to our strong community support and encourage you to give us feedback so we can continue to evolve with your research needs.
Country
The Biobanque québécoise de la COVID-19 (BQC19) is a pan-provincial initiative that collects, stores and shares data and blood samples from COVID-19 patients, both severe and non-severe cases and control cases, in an effort to respond effectively to the public health challenges posed by the pandemic. BQC19 believes that better understanding the disease will help society in returning to social activities and in preparing for future pandemics. It sees access to high-quality samples and data as essential in fulfilling research and works to bring about national and international research collaborations.
Country
ZB MED's Repository for Life Sciences offers authors the chance to publish their scientific texts and research data from the fields of medicine, health, nutritional, environmental and agricultural sciences. In accordance with the principles of Open Access, these publications can be accessed over the Internet without restrictions. There is no charge to publish, archive or use the documents.
MIDRC aims to develop a high-quality repository for medical images related to COVID-19 and associated clinical data, and develop and foster medical image-based artificial intelligence (AI) for use in the detection, diagnosis, prognosis, and monitoring of COVID-19.
IEDB offers easy searching of experimental data characterizing antibody and T cell epitopes studied in humans, non-human primates, and other animal species. Epitopes involved in infectious disease, allergy, autoimmunity, and transplant are included. The IEDB also hosts tools to assist in the prediction and analysis of B cell and T cell epitopes.
INDI was formed as a next generation FCP effort. INDI aims to provide a model for the broader imaging community while simultaneously creating a public dataset capable of dwarfing those that most groups could obtain individually.
To help flattening the COVID-19 curve public health systems need better information on whether preventive measures are working and how the virus may spread. Facebook Data for Good offer maps on population movement that researchers and nonprofits are already using to understand the coronavirus crisis, using aggregated data to protect people’s privacy.
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.
<<<!!!<<< This repository is no longer available. >>>!!!>>> Migration of the data, tools, and services from IRD and ViPR to BV-BRC is complete! We are now in the sunsetting phase of the transition. Starting on October 31, 2022, launching the IRD or ViPR home pages will redirect you to the new BV-BRC home page. The current plan is to completely shut down IRD and ViPR by the end of this calendar year. Although it will still be possible to use those sites until shutdown, we strongly encourage you to start using BV-BRC now.
This Web resource provides data and information relevant to SARS coronavirus. It includes links to the most recent sequence data and publications, to other SARS related resources, and a pre-computed alignment of genome sequences from various isolates. In order to provide free and easy access to genome and protein sequences and associated metadata from the SARS-CoV-2, we created a dedicated Severe acute respiratory syndrome coronavirus 2 data hub. You can access the Results Table on SARS-CoV-2 data hub, by pressing "RefSeq genomes", "nucleotide" or "protein" links on announcement banner located on NCBI home page, in "Find data" navigation menu or using "Up-to-date SARS-CoV-2" shortcut button in "Search by virus" form. SARS-CoV-2 sequences is part of NCBI Virus https://www.re3data.org/repository/r3d100014322
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.